CN111818924B - B-raf激酶抑制剂的结晶盐 - Google Patents

B-raf激酶抑制剂的结晶盐 Download PDF

Info

Publication number
CN111818924B
CN111818924B CN201880081003.9A CN201880081003A CN111818924B CN 111818924 B CN111818924 B CN 111818924B CN 201880081003 A CN201880081003 A CN 201880081003A CN 111818924 B CN111818924 B CN 111818924B
Authority
CN
China
Prior art keywords
cancer
pyridin
pyrrolo
methyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880081003.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111818924A (zh
Inventor
U·韦特曼
G-M·迈尔
B·贝特泽梅尔
O·沙夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xunuo Pharmaceutical Co ltd
Original Assignee
Xunuo Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xunuo Pharmaceutical Co ltd filed Critical Xunuo Pharmaceutical Co ltd
Priority to CN202310913355.9A priority Critical patent/CN116942672B/zh
Publication of CN111818924A publication Critical patent/CN111818924A/zh
Application granted granted Critical
Publication of CN111818924B publication Critical patent/CN111818924B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880081003.9A 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐 Active CN111818924B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310913355.9A CN116942672B (zh) 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577313P 2017-10-26 2017-10-26
US62/577,313 2017-10-26
PCT/US2018/057792 WO2019084459A1 (en) 2017-10-26 2018-10-26 CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310913355.9A Division CN116942672B (zh) 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐

Publications (2)

Publication Number Publication Date
CN111818924A CN111818924A (zh) 2020-10-23
CN111818924B true CN111818924B (zh) 2023-08-15

Family

ID=64277870

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880081003.9A Active CN111818924B (zh) 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐
CN202310913355.9A Active CN116942672B (zh) 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310913355.9A Active CN116942672B (zh) 2017-10-26 2018-10-26 B-raf激酶抑制剂的结晶盐

Country Status (15)

Country Link
US (2) US11306086B2 (https=)
EP (2) EP4245758A3 (https=)
JP (2) JP7230041B2 (https=)
KR (1) KR102820822B1 (https=)
CN (2) CN111818924B (https=)
AU (2) AU2018355528B2 (https=)
BR (1) BR112020008248A2 (https=)
CA (1) CA3080324A1 (https=)
ES (1) ES2947411T3 (https=)
IL (1) IL274027B2 (https=)
MX (1) MX2020004148A (https=)
MY (1) MY203853A (https=)
PH (1) PH12020550485A1 (https=)
SG (1) SG11202003635TA (https=)
WO (1) WO2019084459A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084459A1 (en) 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
JP2022069426A (ja) * 2020-10-23 2022-05-11 マイラン ラボラトリーズ リミテッド テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
CN103476773A (zh) * 2011-02-02 2013-12-25 勃林格殷格翰国际有限公司 用作丝氨酸/苏氨酸激酶抑制剂的新的氮杂吲哚基苯基磺酰胺
CN105801584A (zh) * 2016-03-16 2016-07-27 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
ATE273695T1 (de) 2000-06-28 2004-09-15 Smithkline Beecham Plc Nassvermahlung
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CN102206216B (zh) 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2016167340A1 (ja) 2015-04-16 2016-10-20 日東電工株式会社 Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
WO2019084459A1 (en) 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
CN103476773A (zh) * 2011-02-02 2013-12-25 勃林格殷格翰国际有限公司 用作丝氨酸/苏氨酸激酶抑制剂的新的氮杂吲哚基苯基磺酰胺
CN105801584A (zh) * 2016-03-16 2016-07-27 中国药科大学 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Raf 激酶抑制剂及其耐药机制研究进展";韩伟等;《药学进展》;20161231;参见摘要 *

Also Published As

Publication number Publication date
IL274027A (en) 2020-06-30
EP4245758A3 (en) 2023-12-20
ES2947411T3 (es) 2023-08-08
PH12020550485A1 (en) 2021-03-22
JP2023062074A (ja) 2023-05-02
JP2021501199A (ja) 2021-01-14
US20220204506A1 (en) 2022-06-30
AU2022201044B2 (en) 2023-07-13
BR112020008248A2 (pt) 2020-10-20
RU2020116763A (ru) 2021-11-26
AU2018355528B2 (en) 2021-11-18
CN116942672B (zh) 2026-04-14
CN111818924A (zh) 2020-10-23
US11753409B2 (en) 2023-09-12
KR102820822B1 (ko) 2025-06-16
SG11202003635TA (en) 2020-05-28
IL274027B1 (en) 2023-08-01
RU2020116763A3 (https=) 2022-04-29
WO2019084459A1 (en) 2019-05-02
JP7230041B2 (ja) 2023-02-28
AU2022201044A1 (en) 2022-03-10
EP3700530A1 (en) 2020-09-02
EP4245758A2 (en) 2023-09-20
AU2018355528A1 (en) 2020-05-07
IL274027B2 (en) 2023-12-01
US11306086B2 (en) 2022-04-19
CN116942672A (zh) 2023-10-27
KR20200088345A (ko) 2020-07-22
MY203853A (en) 2024-07-22
MX2020004148A (es) 2022-09-09
CA3080324A1 (en) 2019-05-02
US20200283433A1 (en) 2020-09-10
EP3700530B1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
CN111818924B (zh) B-raf激酶抑制剂的结晶盐
US12312363B2 (en) Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
EP3359542B1 (en) Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN119954807A (zh) 制备抗癌剂的二盐酸盐的方法
RU2798091C2 (ru) Кристаллические соли ингибитора b-raf-киназы
HK40098127A (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621A (en) Crystalline salts of a b-raf kinase inhibitor
HK40035621B (en) Crystalline salts of a b-raf kinase inhibitor
HK1252365B (en) Spiro[3h-indole-3,2’-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant